NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of “Moderate Buy” by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $18.6667.

NPCE has been the topic of a number of research reports. Wall Street Zen raised shares of NeuroPace from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group reissued a “buy” rating on shares of NeuroPace in a research report on Wednesday, January 14th. JPMorgan Chase & Co. lifted their target price on NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research report on Monday, December 29th. Finally, Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a research note on Wednesday.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its holdings in NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after acquiring an additional 1,118 shares during the period. Legal & General Group Plc grew its position in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of NeuroPace during the second quarter worth about $35,000. Quarry LP raised its stake in NeuroPace by 94.9% during the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after purchasing an additional 1,872 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in NeuroPace by 72.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock valued at $71,000 after purchasing an additional 2,668 shares during the period. Institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

NPCE stock opened at $14.03 on Friday. The company has a debt-to-equity ratio of 3.09, a current ratio of 5.28 and a quick ratio of 3.94. NeuroPace has a 1 year low of $7.56 and a 1 year high of $18.98. The company has a market cap of $472.39 million, a P/E ratio of -21.26 and a beta of 1.86. The stock’s fifty day moving average price is $15.54 and its 200-day moving average price is $13.31.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. The company had revenue of $26.59 million for the quarter, compared to the consensus estimate of $24.79 million. NeuroPace had a negative return on equity of 105.67% and a negative net margin of 21.47%. On average, equities analysts forecast that NeuroPace will post -1 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.